Synta’s Ganetespib Could Break The Hsp90i Curse
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.
You may also be interested in...
Miniature By Design: Tarveda's Small Conjugates Could Be Better Fit For HSP90
Biotech's internally derived Pentarins offer the targeting advantages of antibody-drug conjugates in cancer, but with better affinity, pharmacokinetics and deeper tumor penetration.
New Drugs Build On Personalized Medicine Momentum In Lung Cancer
Crop of new treatments with data at the European Society of Medical Oncology meeting includes second-generation inhibitors of ALK and heat shock protein 90.
Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer
Sicker patients may have led to result in GI stromal tumors; lung, breast studies with IPI-504 continue.